We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 78

Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Ongoing Infringement Must be Parsed to Determine Relevant Limitation Periods
  • Bereskin & Parr LLP
  • Canada
  • January 24 2017

In the recent decision of Apotex Inc v AstraZeneca Canada Inc 2017 FCA 9 relating to the drug omeprazole, the Federal Court of Appeal held that in


“Gene Patent” controversy comes to Canada
  • Bereskin & Parr LLP
  • Canada, USA
  • November 4 2014

Patents related to isolated DNA corresponding to a gene, as well as methods claiming the diagnostic use of such DNA sequences are often referred to


Patenting Polymorphs of Crystals Internationally
  • Bereskin & Parr LLP
  • Canada, European Union, Japan, USA
  • June 27 2016

Polymorphs are patentable subject matter in Canada and the U.S. Our prior article discussed some best practices to differentiate a new polymorph from


Biosimilar Approvals in the US and Canada - Sidestepping the 'Patent Dance'
  • Bereskin & Parr LLP
  • Canada, USA
  • January 12 2016

A passing moment of social awkwardness between a couple on a dance floor is nothing compared to the situation when the sidestepping is between two


Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment
  • Bereskin & Parr LLP
  • Canada
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of


The Myriad decision: what is the impact?
  • Bereskin & Parr LLP
  • Canada
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013


Canadian Patent Term Extension - Bill is in the House
  • Bereskin & Parr LLP
  • Canada, European Union
  • November 2 2016

Canada and Europe finally signed off on the Comprehensive Economic and Trade Agreement ("CETA"). Its most significant aspect for the pharma industry


CIPO updates guidance on medical use claims
  • Bereskin & Parr LLP
  • Canada
  • March 23 2015

On March 18, 2015 the Canadian Intellectual Property Office issued a practice notice containing revised examination practice guidelines pertaining to


Looking into the Crystal Ball - Protecting Polymporphs to Lengthen the Drug Patent Life Cycle
  • Bereskin & Parr LLP
  • Canada, USA
  • June 7 2016

Innovative pharmaceutical companies are increasingly attempting to patent improved forms of their original drug compound. Crystalline forms of a drug